Respuestas rápidas
- ¿Para qué se usa Atoltivimab, maftivimab, and odesivimab-ebgn?
- La etiqueta aprobada por la FDA (Inmazeb, Regeneron Pharmaceuticals, Inc., 15 de diciembre de 2025) dice, en inglés: “INMAZEB is indicated for the treatment of infection caused by Orthoebolavirus zairense in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Orthoebolavirus zairense infection […]. …” Esta página no es un consejo médico. Hable con su médico o farmacéutico antes de empezar, dejar o cambiar cualquier medicamento.
- ¿Cuáles son los efectos secundarios de Atoltivimab, maftivimab, and odesivimab-ebgn?
- La sección «Adverse Reactions» (reacciones adversas) de la etiqueta de la FDA (Inmazeb, Regeneron Pharmaceuticals, Inc., 15 de diciembre de 2025) comienza así, en inglés: «The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity Reactions Including Infusion-Associated Events [see Warnings and Precautions (5.1)] The most common adverse events (incidence ≥20%) were pyrexia, chills, tachycardia, tachypnea, and vomiting.» … Esta página no es un consejo médico. Hable con su médico o farmacéutico antes de empezar, dejar o cambiar cualquier medicamento.
- ¿Qué interacciones tiene Atoltivimab, maftivimab, and odesivimab-ebgn?
- La sección «Drug Interactions» (interacciones) de la etiqueta de la FDA (Inmazeb, Regeneron Pharmaceuticals, Inc., 15 de diciembre de 2025) comienza así, en inglés: «Interaction with live vaccine indicated for prevention of Orthoebolavirus zairense infection: No vaccine interaction studies have been performed. INMAZEB may reduce the efficacy of the live vaccine. The interval between live vaccination following initiation of INMAZEB therapy should be in accordance with current vaccination guidelines. (7.1) 7.1 Vaccine Interactions No vaccine-therapeutic interaction studies have been performed in human subjects using INMAZEB.» … Esta página no es un consejo médico. Hable con su médico o farmacéutico antes de empezar, dejar o cambiar cualquier medicamento.
- ¿Atoltivimab, maftivimab, and odesivimab-ebgn tiene una advertencia en recuadro?
- No. Ninguna de las 1 etiquetas de la FDA que encontramos para este medicamento tiene advertencia en recuadro.
- ¿Hay escasez de Atoltivimab, maftivimab, and odesivimab-ebgn?
- La FDA no indica una escasez actual para los productos de este medicamento (datos de la FDA del 13 de noviembre de 2026).
- ¿Se ha retirado del mercado Atoltivimab, maftivimab, and odesivimab-ebgn?
- No aparece ningún retiro vinculado a los productos de este medicamento en los informes de la FDA que usamos.
- ¿Quién fabrica Atoltivimab, maftivimab, and odesivimab-ebgn?
- 1 empresa tiene productos con receta de Atoltivimab, maftivimab, and odesivimab-ebgn en el directorio NDC de la FDA, entre ellas Regeneron Pharmaceuticals, Inc.
Para qué se usa Atoltivimab, maftivimab, and odesivimab-ebgn
Cita de la sección «Indications and Usage» (indicaciones y uso) de la etiqueta aprobada por la FDA. Se muestra en inglés, tal como la publica la FDA.
INMAZEB is indicated for the treatment of infection caused by Orthoebolavirus zairense in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Orthoebolavirus zairense infection […]. …
— Etiqueta de la FDA: Inmazeb, Regeneron Pharmaceuticals, Inc., vigente desde el 15 de diciembre de 2025. Leer la etiqueta completa en DailyMed →
Etiqueta citada: la de la presentación más común (injection, solution, intravenous), Inmazeb, Regeneron Pharmaceuticals, Inc.; abarca 2 productos del directorio NDC de la FDA. Las citas sobre efectos secundarios, interacciones, dosis y embarazo de abajo vienen de esta misma etiqueta.
Esta página no es un consejo médico. Hable con su médico o farmacéutico antes de empezar, dejar o cambiar cualquier medicamento.
Advertencia en recuadro
La advertencia en recuadro («caja negra») es la advertencia más seria de la FDA en la etiqueta de un medicamento, para riesgos graves o mortales.
La etiqueta citada arriba no tiene advertencia en recuadro.
Efectos secundarios de Atoltivimab, maftivimab, and odesivimab-ebgn
Cita de la sección «Adverse Reactions» (reacciones adversas) de la etiqueta aprobada por la FDA. Se muestra en inglés. Avise a su médico de cualquier efecto secundario que le preocupe.
The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity Reactions Including Infusion-Associated Events [see Warnings and Precautions (5.1)] The most common adverse events (incidence ≥20%) were pyrexia, chills, tachycardia, tachypnea, and vomiting.
Leer más de esta sección
(6.1) To report SUSPECTED ADVERSE REACTIONS, contact Regeneron at 1-844-734-6643 or www.regeneron.com/contact or FDA AT 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates may not reflect the rates observed in practice. Overall, 382 adult and pediatric subjects with Orthoebolavirus zairense infection received INMAZEB in one clinical trial (the PALM trial) and as part of an expanded access program conducted in the Democratic Republic of Congo during a Orthoebolavirus zairense outbreak in 2018-2019. In the PALM trial, the safety of INMAZEB was evaluated in a multi-center, open-label, randomized controlled trial, in which 154 subjects (115 adult subjects and 39 pediatric subjects) received INMAZEB [50 mg of atoltivimab, 50 mg of maftivimab, and 50 mg of odesivimab per kg (3 mL/kg)] intravenously as a single infusion and 168 subjects received an investigational control [see Clinical Studies (14)]. All subjects received optimized standard of care treatment. During the same outbreak, INMAZEB [50 mg of atoltivimab, 50 mg of maftivimab, and 50 mg of odesivimab per kg (3 mL/kg)] was given to 228 subjects (190 adult subjects and 38 pediatric subjects) in the expanded access program. The safety data described below is derived from the PALM trial. Table 4 summarizes adverse events that were reported during INMAZEB infusion. The evaluation of adverse events in subjects who received INMAZEB may have been confounded by the signs and symptoms of the underlying Orthoebolavirus zairense infection. The most common adverse events reported in at least 20% of subjects who received INMAZEB were pyrexia (or elevation in fever), chills, tachycardia, tachypnea, and vomiting. The adverse event profile in adult and pediatric subjects treated with INMAZEB was similar. Table 4: Adverse Events That Occurred during INMAZEB Infusion in ≥10% of Adult and Pediatric Subjects in the PALM Trial Adverse Event Adverse events in this table were reported as preferred terms from a list of pre-defined or other adverse events that occurred on the day of infusion, and included signs and symptoms that occurred during or immediately after infusion INMAZEB (N=154) % Control Investigational therapy administered as three separate infusions (N=168) % Pyrexia (Elevation in fever) 54 58 Chills 39 33 Tachycardia 20 32 Tachypnea 19 28 Vomiting Adverse events that were not pre-specified 19 23 Hypotension 15 31 Diarrhea 11 18 Hypoxia 10 11 The following pre-specified symptoms, which were assessed on a daily basis while admitted to the treatment unit, were reported in 40% or more of subjects who received INMAZEB: diarrhea, pyrexia, and vomiting.
Tabla de la etiqueta
| Adverse EventAdverse events in this table were reported as preferred terms from a list of pre-defined or other adverse events that occurred on the day of infusion, and included signs and symptoms that occurred during or immediately after infusion | INMAZEB (N=154) % | ControlInvestigational therapy administered as three separate infusions (N=168) % |
|---|---|---|
| Pyrexia (Elevation in fever) | 54 | 58 |
| Chills | 39 | 33 |
| Tachycardia | 20 | 32 |
| Tachypnea | 19 | 28 |
| VomitingAdverse events that were not pre-specified | 19 | 23 |
| Hypotension | 15 | 31 |
| Diarrhea | 11 | 18 |
| Hypoxia | 10 | 11 |
— Etiqueta de la FDA: Inmazeb, Regeneron Pharmaceuticals, Inc., vigente desde el 15 de diciembre de 2025. Esto es solo una parte de la sección. Leer la etiqueta completa en DailyMed →
Interacciones de Atoltivimab, maftivimab, and odesivimab-ebgn
Cita de la sección «Drug Interactions» (interacciones) de la etiqueta aprobada por la FDA. Se muestra en inglés. Dígale a su farmacéutico todos los medicamentos, vitaminas y productos herbales que toma.
Interaction with live vaccine indicated for prevention of Orthoebolavirus zairense infection: No vaccine interaction studies have been performed. INMAZEB may reduce the efficacy of the live vaccine. The interval between live vaccination following initiation of INMAZEB therapy should be in accordance with current vaccination guidelines. (7.1) 7.1 Vaccine Interactions No vaccine-therapeutic interaction studies have been performed in human subjects using INMAZEB.
Leer más de esta sección
However, because of the potential for INMAZEB to inhibit replication of a live vaccine virus indicated for prevention of Orthoebolavirus zairense infection and possibly reduce the efficacy of the vaccine, avoid the concurrent administration of a live vaccine during treatment with INMAZEB. The interval between live vaccination following initiation of INMAZEB therapy should be in accordance with current vaccination guidelines. The efficacy of INMAZEB among subjects who reported receipt of a recombinant live vaccine prior to their enrollment in the PALM clinical trial was similar to subjects who did not receive a vaccine.
— Etiqueta de la FDA: Inmazeb, Regeneron Pharmaceuticals, Inc., vigente desde el 15 de diciembre de 2025. Leer la etiqueta completa en DailyMed →
Dosis de Atoltivimab, maftivimab, and odesivimab-ebgn
Cita de la sección «Dosage and Administration» (dosis y administración) de la etiqueta aprobada por la FDA. Se muestra en inglés. Su dosis es la que le receta su médico: no la cambie por su cuenta.
The recommended dosage of INMAZEB is 50 mg of atoltivimab, 50 mg of maftivimab, and 50 mg of odesivimab per kg diluted and administered as a single intravenous infusion. (2.1) Refer to the Full Prescribing Information for information on preparation and administration. (2.2) 2.1 Recommended Dosage INMAZEB is a combination of three human monoclonal antibodies co-formulated in a 1:1:1 ratio of atoltivimab, maftivimab, and odesivimab.
Leer más de esta sección
INMAZEB is available as two different strength presentations, containing either 16.67 mg of each antibody per mL or 33.33 mg of each antibody per mL [see Dosage Forms and Strengths (3)]. The recommended dosage of INMAZEB is 50 mg of atoltivimab, 50 mg of maftivimab, and 50 mg of odesivimab per kg diluted and administered as a single intravenous infusion as shown in Table 1 [see Dosage and Administration (2.2)]. 2.2 Preparation and Administration INMAZEB must be prepared and administered under the supervision of a healthcare provider. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. INMAZEB should be clear to slightly opalescent, colorless to pale yellow solution that is free from visible particulates. Discard the vial if the solution is cloudy, discolored or contains particulate matter. Preparation for Intravenous Infusion The recommended dosage is based on 50 mg of atoltivimab, 50 mg of maftivimab, and 50 mg of odesivimab per kg. For example, a patient weighing 50 kg the recommended dosage is 2,500 mg of atoltivimab, 2,500 mg of maftivimab, and 2,500 mg of odesivimab. Determine the number of vials needed based on the calculated dose in volume (mL). – The number of vials needed depends on the INMAZEB strength used. Refer to Table 1 for the corresponding volume per kg needed to withdraw from each available strength presentation to prepare dose. – Multiple INMAZEB vials may be needed. Each vial contains 14.5 mL of INMAZEB solution, regardless of the strength presentation. For example, for a 50 kg patient, the volume of INMAZEB needed is 150 mL (11 vials) if using the 16.67 mg/16.67 mg/16.67 mg per mL solution or 75 mL (6 vials) if using the 33.33 mg/33.33 mg/33.33 mg per mL solution. Table 1: INMAZEB Dosage (Volume per kg) for Intravenous Infusion Preparation When Using the When Using the 241.7 mg of atoltivimab, 241.7 mg of maftivimab, and 241.7 mg of odesivimab per 14.5 mL 483.3 mg of atoltivimab, 483.3 mg of maftivimab, and 483.3 mg of odesivimab per 14.5 mL (16.67 mg /16.67 mg /16.67 mg per mL) Solution (33.33 mg/33.33 mg /33.33 mg per mL) Solution Withdraw 3 mL of solution per kg to prepare the dose Withdraw 1.5 mL of solution per kg to prepare the dose Do not shake the vial. Prior to intravenous infusion, INMAZEB must be further diluted in an intravenous PVC infusion bag containing either 0.9% Sodium Chloride Injection, USP, 5% Dextrose Injection, USP, or Lactated Ringer's Injection, USP. For neonates, the INMAZEB solution should be diluted in 5% Dextrose Injection, USP (see Table 2). The total volume of the infusion solution to be administered is based on the patient's body weight and is specified in Table 2.
Tabla de la etiqueta
| When Using the | When Using the |
|---|---|
| 241.7 mg of atoltivimab, 241.7 mg of maftivimab, and 241.7 mg of odesivimab per 14.5 mL | 483.3 mg of atoltivimab, 483.3 mg of maftivimab, and 483.3 mg of odesivimab per 14.5 mL |
| (16.67 mg /16.67 mg /16.67 mg per mL) Solution | (33.33 mg/33.33 mg /33.33 mg per mL) Solution |
| Withdraw 3 mL of solution per kg to prepare the dose | Withdraw 1.5 mL of solution per kg to prepare the dose |
— Etiqueta de la FDA: Inmazeb, Regeneron Pharmaceuticals, Inc., vigente desde el 15 de diciembre de 2025. Esto es solo una parte de la sección. Leer la etiqueta completa en DailyMed →
Atoltivimab, maftivimab, and odesivimab-ebgn en el embarazo
Cita de la parte sobre embarazo (Pregnancy) de la etiqueta aprobada por la FDA. Se muestra en inglés. Pregunte a su médico antes de tomar cualquier medicamento si está embarazada o planea estarlo.
Risk Summary Orthoebolavirus zairense infection is life-threatening for both the mother and fetus and treatment should not be withheld due to pregnancy (see Clinical Considerations).
Leer más de esta sección
Available data from the PALM trial and an expanded access program in which pregnant women with Orthoebolavirus zairense infection were treated with INMAZEB demonstrate the high rate of maternal and fetal/neonatal morbidity consistent with published literature regarding the risk associated with underlying maternal Orthoebolavirus zairense infection. These data are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal/fetal outcome. Animal reproduction studies with INMAZEB have not been conducted. Human monoclonal antibodies, such as INMAZEB, are transported across the placenta; therefore, INMAZEB has the potential to be transferred from the mother to the developing fetus. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Maternal, fetal and neonatal outcomes are poor among pregnant women infected with Orthoebolavirus zairense. The majority of such pregnancies result in maternal death with miscarriage, stillbirth, or neonatal death. Treatment should not be withheld due to pregnancy.
— Etiqueta de la FDA: Inmazeb, Regeneron Pharmaceuticals, Inc., vigente desde el 15 de diciembre de 2025. Leer la etiqueta completa en DailyMed →
Presentaciones y vía de administración
| Formas farmacéuticas | Inyección, solución |
|---|---|
| Vía | Intravenosa |
| Productos con receta | 2 en el directorio NDC de la FDA |
| Nombres de marca | Inmazeb |
Empresas que tienen este medicamento
Empresas en el directorio NDC de la FDA: la empresa que aparece en el envase (fabricante o distribuidor), con su número de productos con receta.
- Regeneron Pharmaceuticals, Inc.2 productos
Historial de aprobación de la FDA
- BLA: Solicitud de licencia de productos biológicos (BLA): así se aprueba un medicamento biológico (hecho a partir de células vivas).
| Solicitud | Patrocinador | Aprobada | Cambios aprobados después |
|---|---|---|---|
| BLA761169 INMAZEB | Regeneron Pharmaceuticals | 14 de octubre de 2020 | 3, el último 24 de octubre de 2024 2024: Etiquetado · 2022: Etiquetado · 2021: Fabricación (CMC) |
Escasez
La lista de escasez de la FDA no incluye estos productos.
Retiros del mercado
No aparece ningún retiro vinculado a estos productos (por su código NDC) en los informes de la FDA.
Identificadores oficiales
| RxCUI (RxNorm) | 2461536, 2461539, 2571682, 2571685 |
|---|---|
| ID (SPL set ID) de la etiqueta citada | 0536b6fe-6fe5-4fd6-8cc6-1b481945c1fa |
| Etiquetas de la FDA (SPL) | 1 |
| Solicitudes de la FDA | BLA761169 |
| Principios activos (FDA) | ATOLTIVIMAB / MAFTIVIMAB / ODESIVIMAB |
Siguientes pasos
- Encuentre una farmacia cerca de ustedPregunte qué precio le corresponde y si su producto está afectado por un retiro
- Últimos retiros de medicamentos de la FDATodos los medicamentos, los más recientes primero
- Regeneron Pharmaceuticals, Inc.Fabricante o distribuidor
- Todos los medicamentos con receta de la A a la ZBusque por nombre genérico, de marca o en español
Fuentes
- Etiqueta aprobada por la FDA en DailyMed (Biblioteca Nacional de Medicina) — Inmazeb, Regeneron Pharmaceuticals, Inc., vigente desde el 15 de diciembre de 2025; vía openFDA, datos de la FDA exportados el 13 de noviembre de 2026, consultados el 14 de noviembre de 2026
- NDC Directory (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 13 de noviembre de 2026, consultados el 14 de noviembre de 2026
- Drugs@FDA (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 13 de noviembre de 2026, consultados el 14 de noviembre de 2026
- Drug recall enforcement reports (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 10 de noviembre de 2026, consultados el 14 de noviembre de 2026
- Drug shortages (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 13 de noviembre de 2026, consultados el 14 de noviembre de 2026
La FDA ofrece los datos de openFDA tal cual; pueden estar incompletos. Guíese siempre por la etiqueta que viene con su medicamento. Buscador de informes de retiros de la FDA →
Informar un error → · Información para fabricantes de medicamentos